22
228850.KQ Rayence Co. Ltd
- Market cap
- KRW 121B
- P/E
- 30.2x
- P/B
- 0.50x
- ROE
- 7.0%
- Dividend yield
- 1.30%
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 228850.KQ undervalued?
Graham number228850.KQ trades 18.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rayence Co. Ltd fundamental analysis
6 of 22 checks passedROE 0/2
Low return on equity (7.0%), below 10%.
ROA 0/1
Return on assets (6.2%) is below the industry median (6.2%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-167.5%) is below the industry median (0.5%).
Revenue Growth 0/2
Revenue shrank 8.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 62.7x against interest expense, well covered.
PE vs Market 0/1
PE (30.2x) is above the market median (11.3x).
PE vs Industry 0/1
PE (30.2x) is above the industry median (7.6x).
PBV 1/1
Price to book (0.5x) is below the industry median (0.7x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 15.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.3%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Rayence Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rayence Co. Ltd
Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-Si TFT X-ray detectors for applications, such as dental, veterinary, AXI, die-ca…
Full company profileRayence Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rayence Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 98.5B | 107B | 116B | 126B | 102B | 135B | 147B | 143B | 126B | 115B | 146B |
| Gross Profit | 40.3B | 40.5B | 45.3B | 50.9B | 36.8B | 55.0B | 62.6B | 57.9B | 48.2B | 40.9B | 57.1B |
| Operating Income | 18.0B | 17.3B | 18.4B | 19.2B | 1.61B | 18.1B | 22.0B | 19.3B | 6.63B | -3.95B | 12.2B |
| EBITDA | - | - | - | - | - | - | 31.2B | 28.9B | 18.3B | 1.40B | 24.7B |
| Net Income | 14.7B | 14.6B | 15.7B | 14.7B | -1.92B | 14.5B | 22.0B | 19.6B | 7.83B | -5.28B | 16.9B |
| EPS | 905 | 912 | 993 | 933 | -122 | 919 | 1,401 | 1,246 | 498 | -336 | 1,071 |
| Balance Sheet | |||||||||||
| Total Assets | 190B | 196B | 201B | 232B | 225B | 242B | 262B | 277B | 269B | 261B | 272B |
| Total Liabilities | 24.9B | 19.8B | 19.3B | 37.8B | 36.6B | 41.2B | 37.3B | 36.7B | 24.5B | 23.9B | 29.9B |
| Shareholders' Equity | 165B | 177B | 182B | 194B | 188B | 201B | 225B | 240B | 244B | 237B | 242B |
| Cash & Short-term Investments | 85.1B | 90.1B | 86.3B | 89.2B | 101B | 118B | 131B | 149B | 150B | 47.5B | 41.2B |
| Total Debt | 5.37B | 4.19B | - | 5.88B | 5.83B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.37B | 20.6B | 14.7B | 9.45B | 23.3B | 20.9B | 16.6B | 25.8B | 24.8B | 9.21B | 6.12B |
| Capital Expenditure | 15.3B | 4.86B | 2.59B | 7.18B | 2.49B | 1.91B | 1.91B | 4.34B | 8.36B | 2.34B | 4.98B |
| Free Cash Flow | - | - | - | 5.65B | 15.3B | 18.8B | 14.7B | 21.5B | 16.5B | 6.87B | 1.14B |
| Ratios | |||||||||||
| ROE | 8.9% | 8.3% | 8.6% | 7.6% | -1.0% | 7.2% | 9.8% | 8.2% | 3.2% | -2.2% | 7.0% |
| ROA | 7.7% | 7.4% | 7.8% | 6.3% | -0.9% | 6.0% | 8.4% | 7.1% | 2.9% | -2.0% | 6.2% |
| Net Profit Margin | 15.0% | 13.7% | 13.5% | 11.6% | -1.9% | 10.7% | 15.0% | 13.7% | 6.2% | -4.6% | 11.5% |
| Debt to Equity | 0.03x | 0.02x | - | 0.03x | 0.03x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rayence Co. Ltd dividends
- Dividend yield
- 1.30%
- Forward dividend
- 300.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.57B | 100 | - |
| 2024 | KRW 1.57B | 100 | 20.1% |
| 2023 | KRW 2.58B | 164 | 13.2% |
| 2022 | KRW 1.57B | 100 | 7.1% |
| 2021 | KRW 1.57B | 100 | 10.9% |
| 2020 | KRW 2.58B | 164 | - |
| 2019 | KRW 1.57B | 100 | 10.7% |
| 2018 | KRW 1.62B | 102 | 10.3% |
| 2017 | KRW 1.71B | 106 | 11.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Rayence Co. Ltd
- Insiders 64.91%
- Institutions 0.26%
- Public & others 34.84%
- Shares outstanding 15.7M
- Free float 4.94M
Rayence Co. Ltd company profile
- Company name
- Rayence Co. Ltd
- Ticker
- 228850.KQ
- ISIN
- KR7228850004
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 221
- Fiscal year end
- December
- Address
- 14, Samsung 1-ro 1-gil, Hwaseong-si, South Korea
- Phone
- 82 31 8015 6245
- Website
- rayence.com
About Rayence Co. Ltd
Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-Si TFT X-ray detectors for applications, such as dental, veterinary, AXI, die-casting, 2D/3D inline/offline, pipe inspection, etc. It also provides radiography imaging software products, including Xmaru Pro, Xmaru View V1, Xmaru W, Xmaru RF, Xmaru NDT, Vetview Pro, VXV console, Ez Dent Vet, Xmaru PACS, and VXV PACS. In addition, the company offers medical information systems for veterinary hospitals; and engages in veterinary medical device and medicine wholesale and retail business, as well as research and development of process equipment and deposition materials. Further, it is involved in import and sales of X-ray detectors, and manufacturing and sales of ISOs. Rayence Co., Ltd. was founded in 2011 and is headquartered in Hwaseong-si, South Korea.
Rayence Co. Ltd management
2- Mr. YoungKwon SeoInside Director & CEO · born 1972
- Mr. Jae-jeong SeoPresident & Executive Director · born 1974